Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study
Background: Acute respiratory distress syndrome (ARDS) is a severe lung disease with a high rate of morbidity and mortality. Baricitinib and Ruxolitinib, known as Janus kinase (JAK) inhibitors, have shown promise in mitigating the inflammatory response associated with ARDS. This study aims to system...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2025-04-01
|
| Series: | Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://ps.tbzmed.ac.ir/PDF/ps-31-127.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849414595679092736 |
|---|---|
| author | Mehdi Nurmohammad Ahari Ata Mahmoodpoor Hassan Soleimanpour Hamed Valizadeh Shadi Ziaie Hadi Hamishehkar |
| author_facet | Mehdi Nurmohammad Ahari Ata Mahmoodpoor Hassan Soleimanpour Hamed Valizadeh Shadi Ziaie Hadi Hamishehkar |
| author_sort | Mehdi Nurmohammad Ahari |
| collection | DOAJ |
| description | Background: Acute respiratory distress syndrome (ARDS) is a severe lung disease with a high rate of morbidity and mortality. Baricitinib and Ruxolitinib, known as Janus kinase (JAK) inhibitors, have shown promise in mitigating the inflammatory response associated with ARDS. This study aims to systematically compare the effects of baricitinib and ruxolitinib in ARDS patients by pooling data from relevant clinical trials and observational studies. Methods: After searching international databases, including Web of Science (WoS), Medline, Embase, and Google Scholar with MeSH phrases and keywords, 9 studies were obtained for further analysis. The statistical analysis of the data was conducted by using a random-effects model. The I2 index and the chi-squared test were employed to compute heterogeneity. Egger’s tests and Begg’s funnel plots were employed to assess publication bias. Results: A total of 484 ARDS patients were examined from nine articles. The pooled ages of ARDS patients who received baricitinib and ruxolitinib were 63.25 years (61.42-65.08) and 63.12 years (59.53-66.72), respectively. In comparison to standard treatment or a placebo, the pooled data showed a significant decrease in mortality rates among ARDS patients treated with baricitinib and ruxolitinib.; the rate of mortality at 28-days in ARDS patients who received baricitinib and ruxolitinib was 11% (95% CI: 3%-19%), and 37% (95% CI: 31%-43%), respectively. Also, findings revealed that the average duration of invasive ventilation in ARDS patients who received ruxolitinib was 14 days (95% CI: 3%-25%). Our analysis revealed no significant publication bias (p-value>0.05). Conclusion: In conclusion, baricitinib and ruxolitinib have shown promising efficacy, immunogenicity, and safety profiles in ARDS patients. |
| format | Article |
| id | doaj-art-1130dd34260743cf97ef07dce150613a |
| institution | Kabale University |
| issn | 2383-2886 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | Pharmaceutical Sciences |
| spelling | doaj-art-1130dd34260743cf97ef07dce150613a2025-08-20T03:33:46ZengTabriz University of Medical SciencesPharmaceutical Sciences2383-28862025-04-0131212713410.34172/PS.024.40299ps-40299Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis StudyMehdi Nurmohammad Ahari0Ata Mahmoodpoor1Hassan Soleimanpour2Hamed Valizadeh3Shadi Ziaie4Hadi Hamishehkar5Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Anesthesiology and Critical Care Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran.Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Clinical Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.Background: Acute respiratory distress syndrome (ARDS) is a severe lung disease with a high rate of morbidity and mortality. Baricitinib and Ruxolitinib, known as Janus kinase (JAK) inhibitors, have shown promise in mitigating the inflammatory response associated with ARDS. This study aims to systematically compare the effects of baricitinib and ruxolitinib in ARDS patients by pooling data from relevant clinical trials and observational studies. Methods: After searching international databases, including Web of Science (WoS), Medline, Embase, and Google Scholar with MeSH phrases and keywords, 9 studies were obtained for further analysis. The statistical analysis of the data was conducted by using a random-effects model. The I2 index and the chi-squared test were employed to compute heterogeneity. Egger’s tests and Begg’s funnel plots were employed to assess publication bias. Results: A total of 484 ARDS patients were examined from nine articles. The pooled ages of ARDS patients who received baricitinib and ruxolitinib were 63.25 years (61.42-65.08) and 63.12 years (59.53-66.72), respectively. In comparison to standard treatment or a placebo, the pooled data showed a significant decrease in mortality rates among ARDS patients treated with baricitinib and ruxolitinib.; the rate of mortality at 28-days in ARDS patients who received baricitinib and ruxolitinib was 11% (95% CI: 3%-19%), and 37% (95% CI: 31%-43%), respectively. Also, findings revealed that the average duration of invasive ventilation in ARDS patients who received ruxolitinib was 14 days (95% CI: 3%-25%). Our analysis revealed no significant publication bias (p-value>0.05). Conclusion: In conclusion, baricitinib and ruxolitinib have shown promising efficacy, immunogenicity, and safety profiles in ARDS patients.https://ps.tbzmed.ac.ir/PDF/ps-31-127.pdfardsbaricitinibmortality rateruxolitinib |
| spellingShingle | Mehdi Nurmohammad Ahari Ata Mahmoodpoor Hassan Soleimanpour Hamed Valizadeh Shadi Ziaie Hadi Hamishehkar Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study Pharmaceutical Sciences ards baricitinib mortality rate ruxolitinib |
| title | Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study |
| title_full | Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study |
| title_fullStr | Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study |
| title_full_unstemmed | Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study |
| title_short | Evaluation of the Effects of Baricitinib and Ruxolitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Meta-Analysis Study |
| title_sort | evaluation of the effects of baricitinib and ruxolitinib in acute respiratory distress syndrome ards patients a meta analysis study |
| topic | ards baricitinib mortality rate ruxolitinib |
| url | https://ps.tbzmed.ac.ir/PDF/ps-31-127.pdf |
| work_keys_str_mv | AT mehdinurmohammadahari evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy AT atamahmoodpoor evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy AT hassansoleimanpour evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy AT hamedvalizadeh evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy AT shadiziaie evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy AT hadihamishehkar evaluationoftheeffectsofbaricitinibandruxolitinibinacuterespiratorydistresssyndromeardspatientsametaanalysisstudy |